INOVIO PHARMACEUTICALS, INC. - 10-K Filing Summary
Business Context and Reporting Period
Company: INOVIO Pharmaceuticals, Inc. (INO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: INOVIO is a clinical-stage biotechnology company developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. The company utilizes proprietary DNA plasmids and CELLECTRA delivery devices. Its lead candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP). The company has no approved products and generates revenue primarily from collaborative agreements and grants.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $65,343 | $217,756 |
| Net Loss | $(84.9) million | $(107.3) million |
| Operating Expenses | $86.9 million | $112.6 million |
| Research & Development (R&D) | $54.2 million | $75.6 million |
| Cash, Cash Equivalents & Short-Term Investments | $58.5 million | $94.1 million |
| Working Capital | $17.5 million | $62.5 million |
| Accumulated Deficit | $(1.8) billion | $(1.73) billion |
Note: Revenue is derived entirely from the collaborative arrangement with ApolloBio. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 70% to $65,343 from $217,756 in 2024, driven by the timing of milestone payments from the ApolloBio collaboration.
- Expense Reduction: Total operating expenses decreased by 23% ($25.7 million). R&D expenses dropped 28% ($21.4 million), primarily due to lower drug manufacturing and clinical study costs for INO-3107 and reduced contract labor.
- Liquidity Position: Cash and short-term investments declined by approximately $35.6 million year-over-year. Net cash used in operating activities was $88.6 million in 2025 compared to $104.1 million in 2024.
- Financing Activity: The company raised approximately $49.0 million in net proceeds from equity offerings in 2025 (July and November offerings) and $1.1 million from At-The-Market sales.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Status & Outlook
- INO-3107 (RRP): The FDA accepted the Biologic License Application (BLA) in December 2025 for review under the accelerated approval program. However, the FDA granted a standard 10-month review (PDUFA date: October 30, 2026) rather than the requested priority review. The FDA noted a potential issue regarding eligibility for the accelerated approval pathway. INOVIO is awaiting a meeting to discuss this eligibility.
- Competition: In August 2025, the FDA approved PAPZIMEOS for RRP, creating a competitive landscape where INO-3107 would be a second entrant.
- Cash Runway: Management expects current cash resources to fund operations into the fourth quarter of 2026. Substantial doubt exists regarding the company's ability to continue as a going concern beyond this period without additional financing.
Key Risks
- Going Concern: The company has an accumulated deficit of $1.8 billion and insufficient working capital to fund operations for the next 12 months without raising additional capital.
- Regulatory Uncertainty: Risk that the FDA may not approve INO-3107 under the accelerated pathway or may require additional clinical data, delaying commercialization.
- Litigation:
- Securities Litigation: A shareholder class action (filed Feb 2026) and a derivative suit (filed March 2026) allege false/misleading statements regarding the FDA submission and review timeline for INO-3107.
- VGXI Litigation: Ongoing dispute with former contract manufacturer VGXI regarding breach of supply agreement and trade secrets.
- Manufacturing: Reliance on third-party manufacturers for DNA plasmids and single-source suppliers for device components.
Investor Verification Checklist
- Capital Raise Status: Verify if the company has secured additional financing to extend the cash runway beyond Q4 2026, given the "substantial doubt" going concern warning.
- FDA Meeting Outcome: Monitor the outcome of the requested meeting with the FDA regarding the eligibility of INO-3107 for the accelerated approval pathway.
- Litigation Progress: Track developments in the securities class action and derivative suits filed in early 2026 regarding FDA disclosure timelines.
- Competitive Landscape: Assess the market uptake of the recently approved competitor, PAPZIMEOS, and its potential impact on INO-3107's commercial viability.
- Warrant Liability: Review the fair value adjustments of the common stock warrant liabilities ($29.1 million as of Dec 31, 2025), which impact net loss but are non-cash items.